跳至主要内容
临床试验/NCT03728569
NCT03728569终止早期 1 期

Skin Barrier Dysfunction and the Role of Skin Barrier Restoration on Cutaneous and Systemic Inflammation in the Aged Population

University of Michigan2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2018年5月16日最近更新:
适应症

试验速览

阶段
早期 1 期
状态
终止
入组人数
14
试验地点
2
主要终点
Change in skin hydration status in aged and young subjects

研究概览

简要总结

The objective of this exploratory study is to gain an understanding of cutaneous and systemic inflammation and how restoration of the skin barrier through the use of moisturizer may restore the skin barrier function and reduce systemic inflammation in elderly humans compared to the young. The exploratory study will consist of three visits per subject. Subjects will be instructed to apply a moisturizer (Vanicream Moisturizing Skin Cream) over the entire skin surface from the neck down twice daily for up to 30 days.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged group (>70 years old)
  • In good general health
  • Body mass index (BMI) preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2
  • Fitzpatrick skin types I-V
  • Disrupted skin barrier defined as transepidermal water loss (TEWL) >5 g/m2/h on the upper arms or >3 g/m2/h on the buttocks
  • Clinical signs of skin dryness as determined by the investigator.
  • No disease states or physical conditions that would impair evaluation of the biopsy sites
  • Signed, written and witnessed informed consent form
  • Willing to comply with study procedures
  • Young group (18-30 years old)
  • Good general health
  • BMI preferably in the healthy range (approximately 25 kg/m2) and no greater than 30 kg/m2
  • Fitzpatrick skin types I-V
  • Disrupted skin barrier defined as transepidermal water loss (TEWL) >5 g/m2/h on the upper arms or >3 g/m2/h on the buttocks
  • Clinical signs of skin dryness as determined by the investigator
  • No disease states or physical conditions that would impair evaluation of the biopsy sites
  • Signed, written and witnessed informed consent form
  • Willing to comply with study procedures

排除标准

  • Pregnant or lactating women or women contemplating pregnancy for the duration of the protocol (determined by self-report; if subjects are unsure of their pregnancy status, they will be excluded).
  • Frailty as determined by research study nurse
  • History of inflammatory skin conditions such as psoriasis or atopic dermatitis.
  • History of uncontrolled inflammatory or autoimmune disease.
  • History of keloids or any other condition that would complicate wound healing
  • History of allergic reactions to local lidocaine
  • Frequent nonsteroidal anti-inflammatory drug (NSAID) use (not including low dose aspirin) and unwilling/unable to discontinue NSAIDS for 2 weeks prior to enrollment to the end of the study.
  • Systemic steroids (excluding inhaled steroids for asthma) and unwilling/unable to discontinue systemic steroids for 3 weeks prior to enrollment to the end of the study.
  • Topical corticosteroid use within 2 weeks of enrollment.
  • Topical immunomodulation use such as calcineurin inhibitors within 2 weeks of enrollment
  • Other anti-inflammatory or immunodulatory medications (immunosuppression)
  • Received an experimental drug or used an experimental device 30 days prior to admission to the study.

结局指标

主要结局

Change in skin hydration status in aged and young subjects

时间窗: up to 30 days

Trans-epidermal water loss (TEWL) will be performed on the upper arm and buttocks at Visits 1 and 2. This instrument will measure the amount of water that is lost through the skin. The change in skin hydration status in each subject will be assessed and compared between groups.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gary Fisher

Professor

University of Michigan

研究点 (2)

Loading locations...

相似试验